Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

260.17
+0.24000.09%
Volume:1.50M
Turnover:389.05M
Market Cap:459.82B
PE:73.50
High:261.43
Open:259.74
Low:257.87
Close:259.93
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.92
T/O Rate:0.08%
Dividend:6.83
Dividend Rate:2.63%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.48
PE(LYR):110.24

Loading ...

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Allergan Aesthetics Unveils Layered Beauty Report on Global Shift Toward Personalized Aesthetic Care

Reuters
·
Sep 02

AbbVie Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

NetraMark Appoints Abivax Regulatory Chief Keith Fournier to Board

Reuters
·
Sep 01

States Namenda Tablets not Withdrawn for Safety or Effectiveness Reasons - Federal Register

THOMSON REUTERS
·
Aug 31

FDA: Will not Begin Procedures to Withdraw Approval of Abbreviated New Drug Applications That Refer to Namenda Products - Federal Register

THOMSON REUTERS
·
Aug 31

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

TIPRANKS
·
Aug 29

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Reuters
·
Aug 27

Abbvie Submits Regulatory Application to Ema for Skyrizi® (Risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
Aug 27

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Aug 27

Gubra Earns USD 50 Million Milestone as AbbVie Starts Phase 2 Trial of Obesity Drug ABBV-295

Reuters
·
Aug 26

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

Reuters
·
Aug 26

China's Shandong Xinhua Profit Drops on Domestic, International Competition

Reuters
·
Aug 25